http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
The effect of chlorfenapyr exposure on Solenopsis invicta Buren (Hymenoptera: Formicidae)
Liang Yuling,Liang Mingrong,Li Panpan,Song Yunbo,Lu Yongyue 한국응용곤충학회 2023 Journal of Asia-Pacific Entomology Vol.26 No.2
Red imported fire ant (RIFA), Solenopsis invicta Buren, pose a serious risk to the agriculture, environment, and public health in areas invaded by this species. Chemical insecticides have been widely used to prevent and control this plaguing pest. To discover a novel and cost-effective compound for controlling fire ants, we examined the toxic effect of chlorfenapyr on fire ants. While chlorfenapyr exhibited an insufficient horizontal toxicity transfer and knockdown effect to fire ants, feeding with chlorfenapyr solution increased fire ant workers’ gathering abilities while decreasing their walking, climbing, and adhesion ability. The mortalities of the small, medium, and large-size workers were 84.17%, 98.75%, and 82.08%, respectively, after 72 h of treatment with 25, 50, and 200 μg/ml chlorfenapyr. Additionally, females and males exhibited more higher tolerance than workers to chlorfenapyr; meanwhile, females showed a higher resistance than males. That is, the mortality of males was 100% after 120 h of treatment with 6.25 μg/ml chlorfenapyr. In contrast, the mortality of females was 79.05% after 144 h of treatment with 100 μg/ml chlorfenapyr. In addition, the chlorfenapyr bait exhibited significant toxicity on fire ants. Treated with 0.01% chlorfenapyr bait showed a better toxic effect than 0.025% during the period of 2 d-7 d. However, the weight of ant corpses was 1.32 and 1.23 g at 12 d of treatment with 0.025% and 0.01% chlorfenapyr bait, respectively. The present research showed that chlorfenapyr appeared to be an effectively potential toxic compound for developing bait to manage S. invicta.
Huang Lanhui,Liang Min,He Yuling 대한의학회 2023 Journal of Korean medical science Vol.38 No.24
The ravages of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide have sped up the development of relevant vaccines, which is accompanied by public concerns over possible adverse effects. We report a rare case of a 39-year-old woman who suffered from severe hyperglycemia and ketoacidosis with normal hemoglobin A1c four days after SARS-CoV-2 protein subunit vaccine, which is consistent with the diagnosis of fulminant type 1 diabetes (FT1D). She received insulin therapy and recovered after 24 days from onset of the symptoms. This is the first case of new-onset FT1D after SARS-CoV-2 protein subunit vaccination and one of only six that developed after any form of SARS-CoV-2 vaccination. We hope to raise awareness of this potential adverse consequence and recommend careful monitoring after vaccination in patients even without a medical history of diabetes.